WallStSmart

Brainsway Ltd (BWAY)vsStryker Corporation (SYK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 43231% more annual revenue ($26.30B vs $60.70M). BWAY leads profitability with a 15.6% profit margin vs 13.8%. SYK trades at a lower P/E of 33.3x. SYK earns a higher WallStSmart Score of 53/100 (C-).

BWAY

Buy

51

out of 100

Grade: C-

Growth: 10.0Profit: 6.5Value: 4.7Quality: 7.5
Piotroski: 5/9Altman Z: 1.40

SYK

Buy

53

out of 100

Grade: C-

Growth: 5.3Profit: 7.5Value: 3.3Quality: 6.5
Piotroski: 2/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BWAY.

SYKSignificantly Overvalued (-31.3%)

Margin of Safety

-31.3%

Fair Value

$235.85

Current Price

$309.64

$73.79 premium

UndervaluedFair: $235.85Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BWAY3 strengths · Avg: 10.0/10
Revenue GrowthGrowth
35.4%10/10

Revenue surging 35.4% year-over-year

EPS GrowthGrowth
59.8%10/10

Earnings expanding 59.8% YoY

Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

SYK3 strengths · Avg: 8.3/10
Market CapQuality
$118.92B9/10

Large-cap with strong market position

Operating MarginProfitability
24.0%8/10

Strong operational efficiency at 24.0%

Free Cash FlowQuality
$1.22B8/10

Generating 1.2B in free cash flow

Areas to Watch

BWAY3 concerns · Avg: 2.3/10
Market CapQuality
$406.96M3/10

Smaller company, higher risk/reward

P/E RatioValuation
42.1x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.402/10

Distress zone — elevated risk

SYK4 concerns · Avg: 3.3/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

P/E RatioValuation
33.3x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-11.7%2/10

Earnings declined 11.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : BWAY

The strongest argument for BWAY centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 15.6% and operating margin at 12.5%. Revenue growth of 35.4% demonstrates continued momentum.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : BWAY

The primary concerns for BWAY are Market Cap, P/E Ratio, Altman Z-Score. A P/E of 42.1x leaves little room for execution misses.

Bear Case : SYK

The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

BWAY profiles as a growth stock while SYK is a value play — different risk/reward profiles.

SYK carries more volatility with a beta of 0.77 — expect wider price swings.

BWAY is growing revenue faster at 35.4% — sustainability is the question.

SYK generates stronger free cash flow (1.2B), providing more financial flexibility.

Bottom Line

SYK scores higher overall (53/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Brainsway Ltd

HEALTHCARE · MEDICAL DEVICES · USA

Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?